Role and clinical significance of TGF-β1 and TGF-βR1 in malignant tumors (Review)

被引：83
作者：
Wang, Junmin [1 ]
Xiang, Hongjiao [1 ]
Lu, Yifei [1 ]
Wu, Tao [1 ]
机构：
[1] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, 1200 Cailun Rd, Shanghai 201203, Peoples R China
来源：
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE | 2021年 / 47卷 / 04期
基金：
中国国家自然科学基金;
关键词：
transforming growth factor-β 1; receptor; malignant tumor; GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; ANAPLASTIC THYROID-CANCER; SMALL-MOLECULE INHIBITOR; REGULATORY T-CELLS; I KINASE INHIBITOR; TGF-BETA; BREAST-CANCER; UP-REGULATION; COLON-CANCER;
D O I：
10.3892/ijmm.2021.4888
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The appearance and growth of malignant tumors is a complicated process that is regulated by a number of genes. In recent years, studies have revealed that the transforming growth factor-beta (TGF-beta) signaling pathway serves an important role in cell cycle regulation, growth and development, differentiation, extracellular matrix synthesis and immune response. Notably, two members of the TGF-beta signaling pathway, TGF-beta 1 and TGF-beta receptor 1 (TGF-beta R1), are highly expressed in a variety of tumors, such as breast cancer, colon cancer, gastric cancer and hepatocellular carcinoma. Moreover, an increasing number of studies have demonstrated that TGF-beta 1 and TGF-beta R1 promote proliferation, migration and epithelial-mesenchymal transition of tumor cells by activating other signaling pathways, signaling molecules or microRNAs (miRs), such as the NF-kappa B signaling pathway and miR-133b. In addition, some inhibitors targeting TGF-beta 1 and TGF-beta R1 have exhibited positive effects in in vitro experiments. The present review discusses the association between TGF-beta 1 or TGF-beta R1 and tumors, and the development of some inhibitors, hoping to provide more approaches to help identify novel tumor markers to restrain and cure tumors.
引用
收藏
页数：15
相关论文
共 198 条
[31]   Smad-dependent and Smad-independent pathways in TGF-β family signalling [J].
Derynck, R ;
Zhang, YE .
NATURE, 2003, 425 (6958) :577-584
[32]   Breast cancer statistics, 2017, racial disparity in mortality by state [J].
DeSantis, Carol E. ;
Ma, Jiemin ;
Sauer, Ann Goding ;
Newman, Lisa A. ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (06) :439-448
[33]   TGF-β1 and TGF-β2 abundance in liver diseases of mice and men [J].
Dropmann, Anne ;
Dediulia, Tatjana ;
Breitkopf-Heinlein, Katja ;
Korhonen, Hanna ;
Janicot, Michel ;
Weber, Susanne N. ;
Thomas, Maria ;
Piiper, Albrecht ;
Bertran, Esther ;
Fabregat, Isabel ;
Abshagen, Kerstin ;
Hess, Jochen ;
Angel, Peter ;
Coulouarn, Cedric ;
Dooley, Steven ;
Meindl-Beinker, Nadja M. .
ONCOTARGET, 2016, 7 (15) :19499-19518
[34]   Neuropilins: relevant therapeutic targets to improve the treatment of cancers [J].
Dumond, Aurore ;
Demange, Luc ;
Pages, Gilles .
M S-MEDECINE SCIENCES, 2020, 36 (05) :487-496
[35]   Expression of transforming growth factor beta-1 in gastric cancer and in the gastric mucose of first-degree relatives of patients with gastric cancer [J].
Ebert, MPA ;
Yu, J ;
Miehlke, S ;
Fei, G ;
Lendeckel, U ;
Ridwelski, K ;
Stolte, M ;
Bayerdörffer, E ;
Malfertheiner, P .
BRITISH JOURNAL OF CANCER, 2000, 82 (11) :1795-1800
[36]   Ki26894, a novel transforming growth factor-β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line [J].
Ehata, Shogo ;
Hanyu, Aki ;
Fujime, Makoto ;
Katsuno, Yoko ;
Fukunaga, Erina ;
Goto, Kouichiro ;
Ishikawa, Yuichi ;
Nomura, Kimie ;
Yokoo, Hiroshi ;
Shimizu, Toshiyuki ;
Ogata, Etsuro ;
Miyazono, Kohei ;
Shimizu, Kiyoshi ;
Imamura, Takeshi .
CANCER SCIENCE, 2007, 98 (01) :127-133
[37]   Homomeric and heteromeric complexes among TGF-β and BMP receptors and their roles in signaling [J].
Ehrlich, Marcelo ;
Horbelt, Daniel ;
Marom, Barak ;
Knaus, Petra ;
Henis, Yoav I. .
CELLULAR SIGNALLING, 2011, 23 (09) :1424-1432
[38]  
Eli Lilly, CO STUDY LY3200882 P
[39]  
Eli Lilly, 2010, Eli Lilly and Company v. Teva Canada Limited
[40]  
Engle SJ, 1999, CANCER RES, V59, P3379
12345678910